Patents Assigned to Rigshospitalet
-
Publication number: 20230386113Abstract: A medical image processing apparatus according to an embodiment includes processing circuitry. The processing circuitry is configured to obtain a medical image related to the heart. The processing circuitry is configured to generate a polar map indicating myocardial function information on the basis of the medical image. The processing circuitry is configured to cause a display to display a blood vessel image indicating forms of blood vessels included in the heart so as to be superimposed on the polar map. The processing circuitry is configured to receive an operation to designate at least one of the blood vessels displayed over the polar map. The processing circuitry is configured to identify information associated with the blood vessel designated by the operation. The processing circuitry is configured to cause the display to display the information associated with the blood vessel.Type: ApplicationFiled: May 24, 2023Publication date: November 30, 2023Applicants: Rigshospitalet, CANON MEDICAL SYSTEMS CORPORATIONInventors: Takahiko NISHIOKA, Klaus FUGLSANG KOFOED, Mathias BECH MOELLER
-
Patent number: 11819552Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.Type: GrantFiled: February 3, 2021Date of Patent: November 21, 2023Assignees: Rigshospitalet, University of CopenhagenInventors: Christoffer Nielsen, Niels Behrendt, Lars Henning Engelholm
-
Publication number: 20230022032Abstract: The present invention relates to tumor-targeted probes for use as medicaments and for use in treatment of cancer and to methods of treatment wherein such probes are used. The probes consist of a light-absorbing molecule linked directly or via a spacer to a peptide targeting the urokinase-type plasminogen activator receptor (uPAR). When irradiating the light-absorbing molecule of the probe with laser beams from an external source heat will be released locally to tumor cells expressing uPAR resulting in tumor ablation.Type: ApplicationFiled: December 22, 2020Publication date: January 26, 2023Applicant: RIGSHOSPITALETInventor: Andreas KJÆR
-
Patent number: 11554261Abstract: The present disclosure relates to a system for generating a predefined electrical signal in an MR scanner for use in electrical stimulation of a subject during MRI or functional MRI of said subject, wherein said MR scanner is located inside a shielded MRI room. The system comprises a control unit to be located outside the MRI room for generating an electrical signal and an electrical to optical converter to be located outside the MRI room for converting said electrical signal to a corresponding optical signal. An optical transmitting element, such as an optical fiber, is used for transmitting the optical signal into the MRI room, and an optical to electrical converter is used for converting the optical signal to said predefined electrical signal for electrical stimulation of the subject during magnetic resonance imaging. The optical to electrical converter is configured for being located inside the MRI room and for operation during magnetic resonance imaging.Type: GrantFiled: October 5, 2018Date of Patent: January 17, 2023Assignees: Roskilde/Køge Hospital, Rigshospitalet, University Of CopenhagenInventors: Anders Ohlhues Baandrup, Louise Møller Jørgensen, Carsten Thomsen
-
Patent number: 11376230Abstract: The present invention pertains to use of sodium diacetate (NaHAc2) as an antimicrobial agent against bacteria growing in biofilms. The aspects of the invention include a wound care product comprising sodium diacetate, a kit comprising a wound care product, and a method of treating an infected wound.Type: GrantFiled: April 18, 2012Date of Patent: July 5, 2022Assignees: Rigshospitalet Copenhagen University Hospital, Bispebjerg HospitalInventors: Thomas Bjarnsholt, Klaus Kirketerp-Moller, Michael Christian Givskov
-
Publication number: 20220119359Abstract: The present invention relates to novel tetrazine compounds of formula I, wherein one of R1-R5 is 18F, for use in pretargeted in vivo imaging. The compounds are suitable for use in click chemistry, i.e. reactions that join a targeting molecule and a reporter molecule. The invention further relates to precursors to formula I, wherein one of R1-R5 is SnR3, B(OR)2, B(0H)2. Formula (I).Type: ApplicationFiled: November 29, 2019Publication date: April 21, 2022Applicants: KØBENHAVNS UNIVERSITET, RIGSHOSPITALETInventors: Andreas KJÆR, Ida Nymann PETERSEN, Matthias Manfred HERTH, Jesper Langgard KRISTENSEN
-
Publication number: 20210236666Abstract: There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.Type: ApplicationFiled: January 7, 2021Publication date: August 5, 2021Applicant: RIGSHOSPITALETInventors: Andreas KJAER, Morten PERSSON, Michael PLOUG
-
Patent number: 10940213Abstract: The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.Type: GrantFiled: February 3, 2017Date of Patent: March 9, 2021Assignees: Rigshospitalet, University of CopenhagenInventors: Christoffer Nielsen, Niels Behrendt, Lars Henning Engelholm
-
Publication number: 20210015828Abstract: Mirtazapine is useful for the treatment and/or prophylaxis of medication overuse headache based on tension-type headache. Moreover, a pharmaceutical composition and/or the use of mirtazapine for the manufacture of a medicament, are useful against medication overuse headache based on tension-type headache, and the treatment of medication overuse headache based on tension-type headache.Type: ApplicationFiled: October 1, 2020Publication date: January 21, 2021Applicants: Curatis AG, Rigshospitalet - Glostrup, The University of CopenhagenInventors: Arnim PAUSE, Lars Bendtsen, Rigmor Jensen, Jes Olesen
-
Publication number: 20190125903Abstract: There is provided a novel conjugate that binds to the cell surface receptor uPA (uPAR). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing uPAR. The conjugate is capable of carrying a suitable detectable and imageable label that will allow qualitative detection and also quantitation of uPAR levels in vitro and in vivo. This renders the surgical resection of tumors more optimal.Type: ApplicationFiled: September 26, 2018Publication date: May 2, 2019Applicant: RIGSHOSPITALETInventors: Andreas KJAER, Morten PERSSON
-
Patent number: 10246513Abstract: The present invention relates to antagonists or inhibitors, which bind selectively to RANKL/OPGbp and regulate the interaction between RANKL/OPGbp and RANK/OPG. In particular, the present invention relates to an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a RANKL/OPGbppeptide for use in the treatment, prevention or alleviation of male infertility or reduced male fertility such as oligospermia or azospermia.Type: GrantFiled: August 4, 2014Date of Patent: April 2, 2019Assignee: RIGSHOSPITALET COPENHAGEN UNIVERSITY HOSPITALInventor: Martin Blomberg Jensen
-
Publication number: 20180325957Abstract: The present invention relates to adipose-derived stem cells (ASCs) and compositions, as well as methods for preparing and using such ASCs and compositions for therapy.Type: ApplicationFiled: October 21, 2016Publication date: November 15, 2018Applicant: RigshospitaletInventors: Jens Kastrup, Annette Ekblond, Mandana Haack-Sørensen
-
Patent number: 10111969Abstract: There is provided a novel conjugate that binds to the cell surface receptor uPA (uPAR). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing uPAR. The conjugate is capable of carrying a suitable detectable and imageable label that will allow qualitative detection and also quantitation of uPAR levels in vitro and in vivo. This renders the surgical resection of tumors more optimal.Type: GrantFiled: September 3, 2015Date of Patent: October 30, 2018Assignee: RIGSHOSPITALETInventors: Andreas Kjaer, Morten Persson
-
Publication number: 20170334961Abstract: The present invention relates to novel ficolin-associated polypeptides, and polypeptides derived from these ficolin-associated polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases, as well as the use as biomarkers. The present invention further relates to antibodies recognising such novel ficolin-associated polypeptides, and polypeptides derived thereof, nucleic acid molecules encoding such polypeptides, vectors and host cells used in the production of the polypeptides.Type: ApplicationFiled: May 31, 2017Publication date: November 23, 2017Applicants: Rigshospitalet, Københavns Universitet, Syddansk UniversitetInventors: Peter Garred, Tina Hummelshøj Glue, Mikkel-Ole Skjødt
-
Publication number: 20170166616Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: ApplicationFiled: January 6, 2017Publication date: June 15, 2017Applicants: Rigshospitalet, Kobenhavns Universitet, Syddansk UniversitetInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Patent number: 9655840Abstract: The present invention relates to wound care products, devices and methods incorporating acetic acid for the treatment of bacterial infections, in particular bacterial biofilm infections. In particular it relates to a wound care product comprising acetic acid, wherein the product comprises at least one further antibacterial compound; a delivery system comprising a container connected to a means of delivery which is connected to a pad, wherein said container comprises a composition comprising acetic acid and said pad comprises a self-adhesive material; a kit comprising a dressing and an adhesive membrane, wherein the dressing comprises a composition comprising acetic acid; a method of treating a wound comprising a) applying acetic acid to the wound and b) applying a negative pressure to the wound.Type: GrantFiled: December 21, 2010Date of Patent: May 23, 2017Assignees: RIGSHOSPITALET, COPENHAGEN UNIVERSITY HOSPITAL, BISPEBJERG HOSPITALInventors: Michael Christian Givskov, Thomas Bjarnsholt, Klaus Kirketerp-Møller
-
Patent number: 9573984Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: GrantFiled: December 30, 2014Date of Patent: February 21, 2017Assignees: RIGSHOSPITALET, KOBENHAVNS UNIVERSITET, SYDDANSK UNIVERSITETInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Publication number: 20160303040Abstract: The present invention relates to injectable pharmaceutical compositions showing improved storage stability said compositions comprising iloprost.Type: ApplicationFiled: November 18, 2014Publication date: October 20, 2016Applicant: RIGSHOSPITALETInventors: Pär Johansson, Philip Hansen, Jens Kindtler
-
Patent number: 9433589Abstract: The present invention relates to injectable pharmaceutical compositions showing improved storage stability said compositions comprising adrenaline and citric acid showing improved storage stability.Type: GrantFiled: June 17, 2014Date of Patent: September 6, 2016Assignee: RigshospitaletInventors: Philip Hansen, Pär Johansson, Jens Kindtler
-
Patent number: 9381166Abstract: The present invention relates to a novel use and methods of treatment using sympathicomimetic agonists with pro-hemostatic activity.Type: GrantFiled: October 1, 2008Date of Patent: July 5, 2016Assignee: RigshospitaletInventors: Pär Johansson, Niels H. Secher, Louise Bochsen